Pipeline

UNION has built a differentiated mid-to late-stage clinical pipeline with drug candidates in large therapeutic areas.

Preclinical
Phase I
Phase IIa
Phase IIb
Phase III
Status

Orismilast - Immunodermatology

Orismilast*
Atopic dermatitis

Phase 3 in preparation
Orismilast*
Hidradenitis suppurativa

Preparing Phase 2b/3 program
Orismilast*
Psoriasis

Phase 3 ready
Orismilast*
Ulcerative colitis

Phase 2 IIT** ongoing

*) Innovent Biologics has exclusive rights to oral orismilast and an option on topical orismilast for China, HK, Taiwan and Macau; UNION retains remaining worldwide rights.

**) IIT: Investigator initiated trial

Expanded access policy to be found here.